Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Goodwill (2017 - 2025)

Avalo Therapeutics (AVTX) has disclosed Goodwill for 9 consecutive years, with $10.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Goodwill changed 0.0% year-over-year to $10.5 million, compared with a TTM value of $10.5 million through Sep 2025, changed 0.0%, and an annual FY2024 reading of $10.5 million, changed 0.0% over the prior year.
  • Goodwill was $10.5 million for Q3 2025 at Avalo Therapeutics, roughly flat from $10.5 million in the prior quarter.
  • Across five years, Goodwill topped out at $14.4 million in Q1 2021 and bottomed at $10.5 million in Q4 2023.
  • Average Goodwill over 5 years is $12.8 million, with a median of $14.4 million recorded in 2021.
  • The sharpest move saw Goodwill changed 0.0% in 2021, then fell 27.11% in 2023.
  • Year by year, Goodwill stood at $14.4 million in 2021, then changed by 0.0% to $14.4 million in 2022, then dropped by 27.11% to $10.5 million in 2023, then changed by 0.0% to $10.5 million in 2024, then changed by 0.0% to $10.5 million in 2025.
  • Business Quant data shows Goodwill for AVTX at $10.5 million in Q3 2025, $10.5 million in Q2 2025, and $10.5 million in Q1 2025.